Media

On this page, we highlight information of particular relevance for media, including news, events and featured information for journalists with a professional interest in the development and availability of medicines in the European Union. For more information and details relevant for media, see our News & events section. For enquiries from media, please contact the EMA press office.

• List item

  EMA communication activities

  We asked stakeholders for feedback on our communication activities in a survey in 2022 and captured the results in a newly-published report. The findings help us set targets, address areas for improvement and measure progress. For example, we are already adapting our messaging to better suit audience needs and are creating more visuals based on survey insights. We thank all respondents for their feedback.

• List item

  EU agencies promoting a One Health approach

  EMA and other scientific EU agencies responsible for human, animal health and environmental protection have established a task force to coordinate activities and share information, promoting a joined-up One Health approach. A paper is available containing more details.

• List item

  2022 annual report

  Navigate through the digital report to view interviews, short videos and an interactive timeline of the Agency’s main activities in 2022. Read the traditional PDF version to see additional figures and statistics on EMA's regulatory procedures and activities.

• List item

  Human medicines: highlights of 2022

  In 2022, EMA recommended 89 medicines for marketing authorisation. Of these, 41 had a new active substance which had never been authorised in the European Union before. These included two vaccines and two treatments for COVID-19.

• List item

  Veterinary medicines: highlights of 2022

  In 2022, EMA recommended 10 medicines for marketing authorisation. Of these, three had a new active substance. Two are vaccines, including one new biotechnological vaccine.

• List item

  European medicines agencies network strategy to 2025

  The strategy sets out how the network will continue to enable the supply of safe and effective medicines, in the face of developments in science, medicine, digital technologies, globalisation and emerging health threats, such as the COVID-19 pandemic.

• List item

  Coronavirus disease (COVID-19)

  Keep up to date with the latest information on how EMA is handling the COVID-19 pandemic.

• List item

  News and press releases

  Search and filter our news and press releases.

• List item

  Funding, statistics and key operating information

  You can find out more on how we work including statistics and information on financial management.

• List item